JP2013177403A5 - - Google Patents

Download PDF

Info

Publication number
JP2013177403A5
JP2013177403A5 JP2013090484A JP2013090484A JP2013177403A5 JP 2013177403 A5 JP2013177403 A5 JP 2013177403A5 JP 2013090484 A JP2013090484 A JP 2013090484A JP 2013090484 A JP2013090484 A JP 2013090484A JP 2013177403 A5 JP2013177403 A5 JP 2013177403A5
Authority
JP
Japan
Prior art keywords
trp
thr
analog
xaa2
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013090484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013177403A (ja
JP5927139B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013177403A publication Critical patent/JP2013177403A/ja
Publication of JP2013177403A5 publication Critical patent/JP2013177403A5/ja
Application granted granted Critical
Publication of JP5927139B2 publication Critical patent/JP5927139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013090484A 2005-11-28 2013-04-23 強力なコンプスタチン類似体 Active JP5927139B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74020505P 2005-11-28 2005-11-28
US60/740,205 2005-11-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008543388A Division JP5302004B2 (ja) 2005-11-28 2006-11-28 強力なコンプスタチン類似体

Publications (3)

Publication Number Publication Date
JP2013177403A JP2013177403A (ja) 2013-09-09
JP2013177403A5 true JP2013177403A5 (https=) 2014-09-18
JP5927139B2 JP5927139B2 (ja) 2016-05-25

Family

ID=37964706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008543388A Active JP5302004B2 (ja) 2005-11-28 2006-11-28 強力なコンプスタチン類似体
JP2013090484A Active JP5927139B2 (ja) 2005-11-28 2013-04-23 強力なコンプスタチン類似体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008543388A Active JP5302004B2 (ja) 2005-11-28 2006-11-28 強力なコンプスタチン類似体

Country Status (15)

Country Link
US (5) US7888323B2 (https=)
EP (4) EP1960422B1 (https=)
JP (2) JP5302004B2 (https=)
CN (3) CN102977191B (https=)
BR (1) BRPI0619023B1 (https=)
CA (2) CA2631443C (https=)
DK (1) DK1960422T3 (https=)
ES (3) ES2390828T3 (https=)
HR (1) HRP20120621T1 (https=)
IL (2) IL191674A (https=)
PL (1) PL1960422T3 (https=)
PT (1) PT1960422E (https=)
RS (1) RS52429B (https=)
RU (2) RU2474586C2 (https=)
WO (1) WO2007062249A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
US8637325B2 (en) * 2009-02-16 2014-01-28 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
JP2009003429A (ja) * 2007-05-18 2009-01-08 Panasonic Corp アクチュエータ
WO2008153963A1 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
WO2009005651A2 (en) 2007-06-29 2009-01-08 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
AU2008308657A1 (en) * 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
WO2010039690A1 (en) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
PL2424557T3 (pl) 2009-05-01 2018-04-30 The Trustees Of The University Of Pennsylvania Zmodyfikowana kompstatyna z modyfikacjami szkieletu peptydowego i c-końca
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
WO2012050923A2 (en) * 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
WO2012135624A1 (en) 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
CN103687867B (zh) 2011-05-11 2017-02-08 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
CN110229216B (zh) * 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类肽
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
US10213476B2 (en) 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
MX2017005454A (es) 2014-12-23 2017-07-04 Multi Chem Group Llc Agentes depuradores de azufre a base de acrilato para usarse en actividades en pozos petroleros.
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2019113301A (ru) 2016-10-17 2020-11-17 Апеллис Фармасьютикалс, Инк. Комбинированная терапия для ингибирования с3
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
PE20201254A1 (es) 2018-02-27 2020-11-16 Zp Spv 3 K/S Analogos de compstatina y sus usos medicos
EP3645550B1 (en) * 2018-04-06 2021-11-03 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
ES3049784T3 (en) 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses
TW202134435A (zh) 2019-10-22 2021-09-16 美商阿尼拉製藥公司 補體成分ｃ３ ｉｒｎａ組成物及其使用方法
WO2021168320A1 (en) 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
MX2023000679A (es) 2020-07-16 2023-04-18 Zp Spv 3 K/S Inhibidores del factor c3 del complemento y sus usos medicos.
WO2022066774A1 (en) 2020-09-23 2022-03-31 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
JP2024535850A (ja) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
TW202333749A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
CN114605495A (zh) * 2022-04-20 2022-06-10 广州市乾相生物科技有限公司 一种乳四肽的合成方法
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
WO2025229200A1 (en) 2024-05-03 2025-11-06 Bachem Holding Ag Manufacture of disulfide bonded peptides
WO2025245483A1 (en) * 2024-05-24 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods and compositions
CN119176856B (zh) * 2024-11-22 2025-03-18 杭州诺泰诺和生物医药科技有限公司 Pegcetacoplan的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) * 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
JPH05508391A (ja) 1990-04-23 1993-11-25 リュクサニベルシテイト　テ　ユトレヒト 環状ペプチドおよびそれらの使用
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
GB9604865D0 (en) * 1996-03-07 1996-05-08 Imutran Ltd Modified proteins
WO1997033603A1 (en) 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
EP1067950B1 (en) 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
AU2003269389A1 (en) 2002-09-20 2004-04-08 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
MX351152B (es) * 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina

Similar Documents

Publication Publication Date Title
JP2013177403A5 (https=)
RU2008126232A (ru) Эффективные аналоги компстатина
CA2502690C (en) Compstatin analogs with improved activity
AU2012304442B2 (en) Compstatin analogs with improved pharmacokinetic properties
AU2014244860B2 (en) WT1-antigen peptide conjugate vaccine
KR102787208B1 (ko) α4β7 인테그린 티오에테르 펩티드 길항제
KR102397271B1 (ko) Amg 416의 제조 방법
WO2004020462A1 (ja) Ｃｘｃｒ４拮抗薬およびその用途
RU2013149956A (ru) Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
JP2012530145A5 (https=)
EP2154145A2 (en) Dimerized peptide
JP2013518115A5 (https=)
KR20220035199A (ko) 인크레틴 유사체의 제조 방법
JP6934011B2 (ja) Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド
JP2010500298A (ja) 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
Wiśniewski Design of oxytocin analogs
JP2009529509A5 (https=)
ES2308539T3 (es) Ciclacion de peptidos.
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
JP7212942B2 (ja) Ｆｏｘｐ３結合ペプチド及びその使用
JP2011515471A5 (https=)
WO2011098095A1 (en) Peptides binding the tpo receptor
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
Salvadori et al. Antagonism in opioid peptides: the role of conformation